Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults
| Status: | Archived |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
A Phase 1a/b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Reactogenicity, and Immunogenicity of FhCMB HAI-05, a Recombinant Hemagglutinin (rHA) Vaccine Derived From Influenza A/Indonesia/05/2005 (H5N1), in Healthy Adults 18 to 49 Years
The purpose of this study is to assess the safety, immunogenicity,and tolerability of a H5N1
Vaccine in healthy adults.
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials